Novo Nordisk latest outlook trim shows “quick momentum loss”
Novo's CEO Maziar Mike Doustdar has adopted an aggressive M&A stance amid weakening company sales.
Novo's CEO Maziar Mike Doustdar has adopted an aggressive M&A stance amid weakening company sales.
The partnership is the latest in a long line of AI-centric projects in drug discovery and development.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Huawei’s three key steps to drive industrial intelligence forward and unleash AI’s full potential
First responders see AI and other advanced tech as essential
What does the EU Data Act mean for businesses?
Trump blames Covid-19 drugmakers for fuelling CDC turmoil